NurseKim_ATL said:Holding genuinely reduces total burden rather than redistributing it, because the gastric-emptying component adapts.
I dislike how confidently this board tells people to push through. Incidence figures around 20 to 25% at the higher doses are class-typical, but the trials also had a discontinuation column, and "manageable with protocols" is not the same as manageable for everyone.
The figures, for anyone assembling their own picture. Say what you would expect to see if you were wrong, before you look. It is a small discipline and it changes what you notice.
If somebody has the primary source to hand I would rather cite it than paraphrase it.
PeptideChemSF said:I dislike how confidently this board tells people to push through.
Adding the part of the answer the thread has not reached. It helps to say which part of this you are uncertain about. A precise question gets a precise answer; a general one gets everybody’s favourite anecdote.
If somebody has the primary source to hand I would rather cite it than paraphrase it.
PeptideDetective — Independent Peptide Analytics
Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.
View ResultsOne thing that is still open after robert_kc’s answer:
Whether holding at a lower dose for longer actually reduces total side-effect burden or just spreads it out?
OP back with an update, since a thread like this is useless without one.
Update. It was not the dose, it was that I had stopped drinking anything because drinking made me feel full. Fixing that fixed most of it.